Disease · MONDO_0019451
chronic neutrophilic leukemia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. chronic neutrophilic leukemia. Diseases, record MONDO_0019451. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019451
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs5
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| FEDRATINIB | CHEMBL1287853 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RUXOLITINIB PHOSPHATE | CHEMBL1795071 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AZACITIDINE | CHEMBL1489 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MOMELOTINIB | CHEMBL1078178 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OXYGEN | CHEMBL1234886 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets6
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| JAK2 | Tyrosine-protein kinase JAK2 | 3 | Tyrosine-protein kinase JAK2 inhibitor | Phase 2 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| JAK1 | Tyrosine-protein kinase JAK1 | 2 | Tyrosine-protein kinase JAK1 inhibitor | Phase 2 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| ACVR1 | Activin receptor type-1 | 1 | Activin receptor type-1 inhibitor | Early phase 1 | https://conductscience.org/library/genes/90 | Drugs and targets |
| DNMT1 | DNA (cytosine-5)-methyltransferase 1 | 1 | DNA (cytosine-5)-methyltransferase 1 inhibitor | Early phase 1 | https://conductscience.org/library/genes/1786 | Drugs and targets |
| DNMT3A | DNA (cytosine-5)-methyltransferase 3A | 1 | DNA (cytosine-5)-methyltransferase 3A inhibitor | Early phase 1 | https://conductscience.org/library/genes/1788 | Drugs and targets |
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | 1 | Tyrosine-protein kinase receptor FLT3 inhibitor | Phase 2 | https://conductscience.org/library/genes/2322 | Drugs and targets |
Trials4
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02092324 | Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia | Phase 2 | 51 | 2020-11-16 | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Neutrophilic Leukemia | RUXOLITINIB PHOSPHATE | Its record names the disease | ClinicalTrials.gov |
| NCT05177211 | Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) | Phase 2 | 25 | Myeloproliferative Neoplasm, Chronic Neutrophilic Leukemia, MDS | FEDRATINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT03964506 | Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant | Early phase 1 | 24 | Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia, Chronic Monocytic Leukemia, Myelofibrosis, Myelodysplastic/Myeloproliferative Neoplasm | OXYGEN | Its record names the disease | ClinicalTrials.gov | |
| NCT07071155 | Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia | Early phase 1 | 18 | Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Overlap Neoplasms, Chronic Neutrophilic Leukemia | AZACITIDINE, MOMELOTINIB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019451
GET https://conductscience.org/api/diseases/v1/MONDO_0019451/drugs